Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06236139CT.gov Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Steap1 Car T-Cells (this asset) | Fred Hutchinson Cancer Center | P1/2 | CC · 45 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Prednisone | Mayo Clinic | P3 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Anti-Steap1 Car T-Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P1/2 | CCC · 48 |
| Prostate Cancer | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Steap1 Car T-Cells in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-steap1-car-t-cells-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →